These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

737 related articles for article (PubMed ID: 22179489)

  • 21. Safety and efficacy of high-dose intravenous iron carboxymaltose vs. iron sucrose for treatment of postpartum anemia.
    Pfenniger A; Schuller C; Christoph P; Surbek D
    J Perinat Med; 2012 Apr; 40(4):397-402. PubMed ID: 22752771
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepcidin levels predict nonresponsiveness to oral iron therapy in patients with iron deficiency anemia.
    Bregman DB; Morris D; Koch TA; He A; Goodnough LT
    Am J Hematol; 2013 Feb; 88(2):97-101. PubMed ID: 23335357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymaltose for the Treatment of Iron-Deficiency Anemia in Patients With Inflammatory Bowel Disease: A Randomized Controlled Noninferiority Trial.
    Howaldt S; Domènech E; Martinez N; Schmidt C; Bokemeyer B
    Inflamm Bowel Dis; 2022 Mar; 28(3):373-384. PubMed ID: 33988236
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inflammatory bowel disease and anemia: intravenous iron treatment.
    Kangaspunta M; Haapamäki J; Färkkilä M; Arkkila P
    Scand J Gastroenterol; 2018 Apr; 53(4):430-434. PubMed ID: 29468908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous iron treatment in pregnancy: comparison of high-dose ferric carboxymaltose vs. iron sucrose.
    Christoph P; Schuller C; Studer H; Irion O; De Tejada BM; Surbek D
    J Perinat Med; 2012 May; 40(5):469-74. PubMed ID: 22945271
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and tolerability of intravenous ferric carboxymaltose in patients with iron deficiency anemia.
    Bailie GR; Mason NA; Valaoras TG
    Hemodial Int; 2010 Jan; 14(1):47-54. PubMed ID: 19888949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study.
    Charytan C; Bernardo MV; Koch TA; Butcher A; Morris D; Bregman DB
    Nephrol Dial Transplant; 2013 Apr; 28(4):953-64. PubMed ID: 23222534
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ferric carboxymaltose improves exercise capacity and quality of life in patients with pulmonary arterial hypertension and iron deficiency: a pilot study.
    Viethen T; Gerhardt F; Dumitrescu D; Knoop-Busch S; ten Freyhaus H; Rudolph TK; Baldus S; Rosenkranz S
    Int J Cardiol; 2014 Aug; 175(2):233-9. PubMed ID: 24880481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Intravenous Ferric Carboxy-maltose in Pregnant Women with Iron Deficiency Anaemia.
    Mishra V; Gandhi K; Roy P; Hokabaj S; Shah KN
    J Nepal Health Res Counc; 2017 Sep; 15(2):96-99. PubMed ID: 29016575
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Switching patients with non-dialysis chronic kidney disease from oral iron to intravenous ferric carboxymaltose: effects on erythropoiesis-stimulating agent requirements, costs, hemoglobin and iron status.
    Toblli JE; Di Gennaro F
    PLoS One; 2015; 10(4):e0125528. PubMed ID: 25928811
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study.
    Covic A; Mircescu G
    Nephrol Dial Transplant; 2010 Aug; 25(8):2722-30. PubMed ID: 20190247
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of intravenous ferric carboxymaltose in the treatment of postpartum iron deficiency anemia.
    Breymann C; Gliga F; Bejenariu C; Strizhova N
    Int J Gynaecol Obstet; 2008 Apr; 101(1):67-73. PubMed ID: 18234203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized Controlled Trial of Intravenous Ferric Carboxymaltose vs Oral Iron to Treat Iron Deficiency Anemia After Variceal Bleed in Patients With Cirrhosis.
    Tabish M; Agarwal S; Gopi S; Rana R; Ahmed S; Gunjan D; Sharma S; Saraya A
    Am J Gastroenterol; 2024 Oct; 119(10):2061-2069. PubMed ID: 38517084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials.
    Naqash A; Ara R; Bader GN
    BMC Womens Health; 2018 Jan; 18(1):6. PubMed ID: 29304848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with ferric carboxymaltose in the treatment of cancer- and chemotherapy-associated anaemia.
    Steinmetz T; Tschechne B; Harlin O; Klement B; Franzem M; Wamhoff J; Tesch H; Rohrberg R; Marschner N
    Ann Oncol; 2013 Feb; 24(2):475-482. PubMed ID: 23071262
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of ferric carboxymaltose immediately after infliximab administration, in a single session, in inflammatory bowel disease patients with iron deficiency: a pilot study.
    Cortes X; Borrás-Blasco J; Molés JR; Boscá M; Cortés E
    PLoS One; 2015; 10(5):e0128156. PubMed ID: 26011514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose intravenous treatment in iron deficiency anaemia in inflammatory bowel disease: early efficacy and impact on quality of life.
    García-López S; Bocos JM; Gisbert JP; Bajador E; Chaparro M; Castaño C; García-Erce JA; Gomollón F
    Blood Transfus; 2016 May; 14(2):199-205. PubMed ID: 27177405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety and efficacy of intravenous ferric carboxymaltose in Japanese patients with iron-deficiency anemia caused by digestive diseases: an open-label, single-arm study.
    Ikuta K; Ito H; Takahashi K; Masaki S; Terauchi M; Suzuki Y
    Int J Hematol; 2019 Jan; 109(1):50-58. PubMed ID: 30194568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.